A carregar...

Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib

BACKGROUND: KIT mutations are the predominant driver mutations in gastrointestinal stromal tumors (GISTs), and targeted therapy against KIT has improved treatment outcome dramatically. However, gaining secondary mutation of KIT confers drug resistance of GISTs leading to treatment failure. RESULTS:...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Biosci
Main Authors: Zhu, Guangrong, Shi, Jun, Zhang, Shaoting, Guo, Yue, Huang, Ling, Zhao, Hui, Jiang, Yideng, Sun, Jianmin
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7017564/
https://ncbi.nlm.nih.gov/pubmed/32082541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13578-020-0377-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!